DataJoint, a leading informatics platform transforming data management and analysis in the life sciences, has announced the appointment of John Apathy as a Strategic Advisor. The move strengthens DataJoint’s expertise in AI-powered research workflows and data-driven transformation across pharmaceutical and scientific R&D.
Apathy brings over 35 years of experience in consulting and technology leadership in the biopharma sector, with a focus on leveraging advanced data and digital approaches to accelerate discovery and precision medicine. Currently Chief Solutions Officer at XponentL Data, a Genpact company, he advises clients on maximizing the value of AI and data in research operations.
Previously, Apathy served as global Head of Digital/IT for Research and Early Development at Bristol Myers Squibb, leading initiatives that integrated high-performance computing, translational informatics, and AI to drive scientific innovation. His career also spans leadership roles at Celgene, GSK, Wyeth, Eli Lilly, Accenture, and PA Consulting Group, giving him deep insight into enterprise-scale R&D transformation.
“Digital transformation is accelerating through the application of AI in life sciences R&D, and platforms like DataJoint are essential to advancing our understanding of complex human biology,” said John Apathy. “DataJoint’s SciOps platform integrates instruments, data, code, and computation into automated, AI-ready workflows. I’m excited to contribute to improving the productivity and impact of research.”
DataJoint’s Impact on Life Sciences
Used by over 100 research labs, including Johns Hopkins, Harvard, UCSF, and UCL, DataJoint addresses challenges of fragmented data management and irreproducible workflows. Its SciOps platform enables researchers to integrate experiments, computation, and analytics, fostering collaboration and accelerating discoveries.
“John’s deep experience leading digital and data transformation initiatives in biopharma R&D makes him an outstanding addition to our advisory team,” said Jim Olson, CEO of DataJoint. “His guidance will help accelerate growth and expand our impact in life sciences, where data integration and reproducibility are more critical than ever.”
By bringing in advisors like Apathy, DataJoint underscores its commitment to AI-ready scientific research, computational reproducibility, and the next generation of data-driven life sciences innovation.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
